Hologic Inc. closed 22.70% short of its 52-week high of $84.67, which the company reached on August 9th.

Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company ...

Medical technology company Hologic (NASDAQ:HOLX) in Q4 CY2024, but sales were flat year on year at $1.02 billion. On the ...

RBC Capital analyst Conor McNamara lowered the firm’s price target on Hologic (HOLX) to $85 from $88 and keeps a Sector Perform rating on the ...

Raymond James lowered the firm’s price target on Hologic (HOLX) to $90 from $95 and keeps an Outperform rating on the shares. Hologic’s print ...

Q1 2025 Management View CEO Steve MacMillan announced Q1 2025 revenue of $1.022 billion, reflecting a 1% increase on a constant currency basis, aligned with the company’s guidance. Non-GAAP EPS ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

US Open champion Bianca Andreescu's return to the Hologic WTA Tour will be delayed until the spring clay-court season after a recent emergency appendectomy.

Hologic has officially announced the End-of-Sale and End-of-Life for the Hologic Fluoroscan InSight FD Mini C-Arm, with sales discontinuing on September 30, 2025. While Hologic has stated they will ...

Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates ...

Learn more about whether Alcon Inc. or Hologic, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.